Published in N Engl J Med on August 08, 1996
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
Survival of children with sickle cell disease. Blood (2004) 2.84
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood (2012) 2.72
Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest (2003) 2.54
Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest (2007) 2.47
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA (2014) 2.01
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood (2011) 1.90
Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest (2000) 1.86
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant (2009) 1.46
The performance of the PedsQL generic core scales in children with sickle cell disease. J Pediatr Hematol Oncol (2008) 1.42
Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants. Blood (2015) 1.42
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood (2006) 1.31
Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant (2012) 1.21
Impact of family income and sickle cell disease on the health-related quality of life of children. Qual Life Res (2008) 1.20
A psychometric evaluation of the PedsQL Family Impact Module in parents of children with sickle cell disease. Health Qual Life Outcomes (2009) 1.12
Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum (2006) 1.04
PedsQL™ sickle cell disease module: feasibility, reliability, and validity. Pediatr Blood Cancer (2013) 1.00
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica (2014) 1.00
Bone marrow transplantation in sickle cell anemia--the dilemma of choice. N Engl J Med (1996) 0.98
Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Curr Opin Oncol (2009) 0.97
Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Biol Blood Marrow Transplant (2007) 0.95
Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts. Exp Hematol (2007) 0.94
Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Arch Dis Child (1999) 0.94
Exchange transfusion therapy and its effects on real-time microcirculation in pediatric sickle cell anemia patients: an intravital microscopy study. J Pediatr Hematol Oncol (2012) 0.93
Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant (2013) 0.92
Selective resistance of CD44hi T cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation. J Immunol (2011) 0.92
Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model. Bone Marrow Transplant (2013) 0.91
Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol (2012) 0.89
PedsQL™ Multidimensional Fatigue Scale in sickle cell disease: feasibility, reliability, and validity. Pediatr Blood Cancer (2013) 0.88
Increased reticulocytosis during infancy is associated with increased hospitalizations in sickle cell anemia patients during the first three years of life. PLoS One (2013) 0.88
Novel insights in the management of sickle cell disease in childhood. World J Clin Pediatr (2016) 0.86
The effect of parental mental health on proxy reports of health-related quality of life in children with sickle cell disease. Pediatr Blood Cancer (2010) 0.86
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant (2014) 0.85
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. Biol Blood Marrow Transplant (2014) 0.85
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells. Biol Blood Marrow Transplant (2013) 0.84
Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease: Problems and Solutions. Turk J Haematol (2015) 0.82
Hematopietic stem cell transplantation in thalassemia and related disorders. Mediterr J Hematol Infect Dis (2009) 0.82
Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations. J Blood Med (2015) 0.81
Treating hemoglobinopathies using gene-correction approaches: promises and challenges. Hum Genet (2016) 0.81
Advances in sickle cell therapies in the hydroxyurea era. Mol Med (2014) 0.80
Haematopoietic stem cell transplantation in Nigerian sickle cell anaemia children patients. Niger Med J (2015) 0.80
Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer (2011) 0.80
Amelioration of murine sickle cell disease by nonablative conditioning and γ-globin gene-corrected bone marrow cells. Mol Ther Methods Clin Dev (2015) 0.80
Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. Bone Marrow Transplant (2014) 0.80
Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. Bone Marrow Transplant (2013) 0.79
Sickle cell disease in children. Drugs (2012) 0.78
Haematology in Africa. Br J Haematol (2011) 0.77
Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions. Hematol Oncol Clin North Am (2014) 0.77
Zinc finger nucleases for targeted mutagenesis and repair of the sickle-cell disease mutation: An in-silico study. BMC Blood Disord (2012) 0.77
Adult haematopoietic stem cell niches. Nat Rev Immunol (2017) 0.77
Hematopoietic stem cell function in a murine model of sickle cell disease. Anemia (2012) 0.76
Blood and marrow transplantation for sickle cell disease: is less more? Blood Rev (2014) 0.75
Pediatric sickle cell disease: past successes and future challenges. Pediatr Res (2016) 0.75
A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood (2016) 0.75
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood (2015) 0.75
Magnetic resonance imaging in pediatric sickle cell anemia. Exp Ther Med (2016) 0.75
Invasive pulmonary aspergillosis in a haematopoietic stem cell transplant recipient with sickle cell disease: a successful treatment. Mediterr J Hematol Infect Dis (2015) 0.75
Reduction of intramedullary apoptosis after stem cell transplantation in black african variant of pediatric sickle cell anemia. Mediterr J Hematol Infect Dis (2014) 0.75
Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 0.75
Treosulfan-Based Conditioning Regimen in Sibling and Alternative Donor Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease. Mediterr J Hematol Infect Dis (2017) 0.75
Allogeneic stem cell transplantation for sickle cell disease. Curr Opin Hematol (2016) 0.75
Sickle cell disease expenditures and outcomes. Public Health Rep (1997) 0.75
Faster and more accurate graphical model identification of tandem mass spectra using trellises. Bioinformatics (2016) 0.75
Pediatric hematology providers on referral for transplant evaluation for sickle cell disease: a regional perspective. J Pediatr Hematol Oncol (2014) 0.75
Mouse nidovirus LDV infection alleviates graft versus host disease and induces type I IFN-dependent inhibition of dendritic cells and allo-responsive T cells. Immun Inflamm Dis (2017) 0.75
Current concepts in the management of stroke in children with sickle cell disease. Childs Nerv Syst (2011) 0.75
Enhanced Long-Term Brain MRI Evaluation of Children with Sickle Cell Disease Following Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2017) 0.75
Man and his dog. Science (1997) 23.86
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science (1998) 4.58
Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med (1977) 4.22
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
What did audit achieve? Lessons from preliminary evaluation of a year's medical audit. BMJ (1990) 4.03
Mortality rates in displaced and resident populations of central Somalia during 1992 famine. Lancet (1993) 3.84
Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis (1997) 3.67
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33
A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med (1995) 3.24
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22
Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect (1993) 3.06
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95
Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am (1999) 2.86
Thrombogenesis in sickle cell disease. J Lab Clin Med (2001) 2.75
The canine major histocompatibility complex. Supertypic specificities defined by the primed lymphocyte test (PLT). Immunogenetics (1984) 2.72
Prognostic nutritional index in gastrointestinal surgery. Am J Surg (1980) 2.66
The clinical impact of increased sensitivity PT and APTT coagulation assays. Am J Clin Pathol (1999) 2.66
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
The application of mitochondrial DNA typing to the study of white Caucasian genetic identification. Int J Legal Med (1993) 2.64
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood (1999) 2.59
Reduction of operative morbidity and mortality by combined preoperative and postoperative nutritional support. Ann Surg (1980) 2.43
Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med (1992) 2.42
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42
Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics (1995) 2.38
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med (1998) 2.36
Professional negligence: a duty of candid disclosure? BMJ (1995) 2.33
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
alpha-Globin gene organisation in blacks precludes the severe form of alpha-thalassaemia. Nature (1979) 2.25
A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr (2001) 2.22
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19
Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol (2005) 2.16
Idiopathic disseminated bacillus Calmette-Guérin infection: a French national retrospective study. Pediatrics (1996) 2.14
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10
The vaso-occlusive crisis of sickle cell disease. BMJ (1991) 2.09
Intracranial aneurysms in sickle-cell anemia: clinical features and pathogenesis. J Neurosurg (1991) 2.06
The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol (1996) 2.05
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Liver transplantation in hemophilia A. Blood (1987) 1.98
Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology (1998) 1.92
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol (2000) 1.92
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 1.91
The Washington State Intergenerational Study of Birth Outcomes: methodology and some comparisons of maternal birthweight and infant birthweight and gestation in four ethnic groups. Paediatr Perinat Epidemiol (1999) 1.90
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89
Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis (2000) 1.87
Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med (1982) 1.85
A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83
Technique for human marrow grafting. Blood (1970) 1.83
Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol (1996) 1.82
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood (1997) 1.80
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood (1995) 1.79
Infection with varicella-zoster virus after marrow transplantation. J Infect Dis (1985) 1.77
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood (1996) 1.77
Allogeneic marrow grafting for treatment of aplastic anemia. Blood (1974) 1.76
Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant (1993) 1.72
Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72
Acute chest syndrome in sickle-cell disease. Lancet (1984) 1.72
Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation (1996) 1.72
Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood (1995) 1.72
Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr (2001) 1.71
Marrow transplantation for thalassaemia. Lancet (1982) 1.71
STUDIES ON CERTAIN CHARACTERISTICS OF CLOSTRIDIUM CHAUVEI AND CLOSTRIDIUM EDEMATIS. J Bacteriol (1925) 1.69
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 1.69
Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic-specific rates. Br J Haematol (1999) 1.67
Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood (2001) 1.66